Novartis’ radioligand therapy Lutathera could soon face generic competitionnews2026-04-23T17:49:23+00:00April 23rd, 2026|Endpoints News|
Amneal to buy a biosimilar company; Samsung Bio workers protestnews2026-04-23T14:00:25+00:00April 23rd, 2026|Endpoints News|
AbbVie’s North Carolina $1.4B manufacturing site to finish during Trump’s termnews2026-04-22T18:38:54+00:00April 22nd, 2026|Endpoints News|
Biovac gets $108M backing for vaccine factory in South Africanews2026-04-17T13:32:30+00:00April 17th, 2026|Endpoints News|
MSF says Gilead’s lenacapavir supply ‘not nearly enough’; PolyPeptide’s strategic reviewnews2026-04-16T14:00:25+00:00April 16th, 2026|Endpoints News|
White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says news2026-04-13T18:52:23+00:00April 13th, 2026|Endpoints News|
Regeneron wades into radiopharma through $40M upfront deal with Telixnews2026-04-13T14:51:29+00:00April 13th, 2026|Endpoints News|
Shionogi’s BARDA contract; Scinai finalizes CDMO unit setupnews2026-04-09T14:31:05+00:00April 9th, 2026|Endpoints News|
BioNTech to shutter Singapore HQ after ‘comprehensive review’news2026-04-07T11:20:12+00:00April 7th, 2026|Endpoints News|
Trump signs order to put 100% pharma tariffs on drugs, countries without trade dealsnews2026-04-02T19:59:29+00:00April 2nd, 2026|Endpoints News|
